Is Zeltiq Aesthetics Inc’s Fuel For Real? The Stock Was Bought By Option Traders

 Is Zeltiq Aesthetics Inc's Fuel For Real? The Stock Was Bought By Option Traders

In today’s session Zeltiq Aesthetics Inc (ZLTQ) registered an unusually high (456) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious ZLTQ increase. With 456 contracts traded and 20574 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: ZLTQ161118C00040000 closed last at: $2.8 or 21.7% up. About 28,941 shares traded hands. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has risen 42.96% since April 20, 2016 and is uptrending. It has outperformed by 38.41% the S&P500.

Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) Ratings Coverage

Out of 7 analysts covering Zeltiq Aesthetics (NASDAQ:ZLTQ), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Zeltiq Aesthetics has been the topic of 13 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) earned “Outperform” rating by William Blair on Wednesday, August 26. As per Friday, January 22, the company rating was upgraded by Griffin Securities. Canaccord Genuity maintained Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) rating on Thursday, November 10. Canaccord Genuity has “Buy” rating and $45 price target. Leerink Swann maintained it with “Outperform” rating and $42 target price in Wednesday, October 28 report. The firm has “Buy” rating by Brean Capital given on Wednesday, April 13. On Wednesday, September 21 the stock rating was maintained by Stifel Nicolaus with “Buy”. On Wednesday, October 28 the stock rating was maintained by Maxim Group with “Buy”. The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has “Buy” rating given on Tuesday, September 1 by Piper Jaffray. The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has “Neutral” rating given on Tuesday, August 9 by JP Morgan.

According to Zacks Investment Research, “Zeltiq Aesthetics Inc. is a medical technology company engaged in designing, development and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. The Company offers CoolSculpting System and other products to the dermatologists, plastic surgeons, and aesthetic specialists in North America and internationally. Zeltiq Aesthetics Inc. is based in Pleasanton, California.”

Insitutional Activity: The institutional sentiment increased to 1.47 in 2016 Q2. Its up 0.11, from 1.36 in 2016Q1. The ratio increased, as 28 funds sold all Zeltiq Aesthetics Inc shares owned while 42 reduced positions. 25 funds bought stakes while 70 increased positions. They now own 43.91 million shares or 2.50% more from 42.84 million shares in 2016Q1.
Eagle Asset Mgmt Inc owns 1.47 million shares or 0.28% of their US portfolio. The Minnesota-based Thrivent Fincl For Lutherans has invested 0% in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Bancorp Of America Corp De last reported 154,647 shares in the company. The New York-based Pinebridge Limited Partnership has invested 0.01% in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Ls Invest Advisors Limited Liability Com last reported 0% of its portfolio in the stock. Tiaa Cref Inv Management Lc last reported 108,150 shares in the company. Teachers Advsr has 0% invested in the company for 56,367 shares. Mycio Wealth Partners Limited Liability holds 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 52 shares. Arizona State Retirement Systems holds 0.01% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 16,800 shares. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Aisling Cap Limited Com, a New York-based fund reported 2.11M shares. Tci Wealth Advsrs, a Arizona-based fund reported 63 shares. Alpinvest Prns Bv, a Netherlands-based fund reported 43,226 shares. First Trust Advisors Lp holds 0% or 15,320 shares in its portfolio. Vanguard Group has invested 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ).

Insider Transactions: Since July 11, 2016, the stock had 0 insider buys, and 19 insider sales for $27.17 million net activity. 10,000 shares were sold by Foley Mark J, worth $395,430 on Monday, November 14. Shares for $111,978 were sold by Hauser Bradley. Shares for $240,123 were sold by Sullivan Keith J on Monday, July 11. On Thursday, September 15 Lamm Carl sold $125,000 worth of the stock or 3,125 shares. Shares for $300,612 were sold by OBOYLE KEVIN C. The insider SCHIFF ANDREW N sold $18.20M. Garcia Sergio sold $781,548 worth of stock or 20,000 shares.

ZELTIQ Aesthetics, Inc. is a medical technology company. The company has a market cap of $1.64 billion. The Firm focuses on developing and commercializing products utilizing its controlled-cooling technology platform. It has a 55.74 P/E ratio. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges.

ZLTQ Company Profile

ZELTIQ Aesthetics, Inc., incorporated on March 22, 2005, is a medical technology company. The Firm focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Firm sell its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system.

More recent Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) news were published by: Fool.com which released: “Why Zeltiq Aesthetics Inc. Is Soaring Today” on November 10, 2016. Also Nasdaq.com published the news titled: “Earnings Reaction History: ZELTIQ Aesthetics, Inc., 40.0% Follow-Through …” on March 06, 2016. Fool.com‘s news article titled: “Zeltiq Aesthetics Earnings: Keeping Up Appearances” with publication date: August 08, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment